PT - JOURNAL ARTICLE AU - Álvarez-Díaz, Diego A. AU - Laiton-Donato, Katherine AU - Torres-García, Orlando Alfredo AU - Ruiz-Moreno, Hector Alejandro AU - Franco-Muñoz, Carlos AU - Beltran, Maria Angie AU - Mercado-Reyes, Marcela AU - Rueda, Miguel Germán AU - Muñoz, Ana Luisa TI - Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage AID - 10.1101/2021.09.13.21263430 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.13.21263430 4099 - http://medrxiv.org/content/early/2021/09/16/2021.09.13.21263430.short 4100 - http://medrxiv.org/content/early/2021/09/16/2021.09.13.21263430.full AB - The E484K mutation at the SARS-CoV-2 Spike protein emerged independently in different variants around the world, probably as part of the ongoing adaptation of the virus to the human host, and has been widely associated with immune escape from neutralizing antibodies generated during previous infection or vaccination. In this work, the B.1+L249S+E484K lineage was isolated along with A.1, B.1.420 and B.1.111 SARS-CoV-2 lineages without the E484K mutation and the neutralizing titer of convalescent sera was compared using microneutralization assays. While no significant differences in the neutralizing antibody titers were found between A1 and B lineages without the E484K mutation, the neutralizing titers against B.1+L249S+E484K were 1.5, 1.9, 2.1, and 1.3-fold lower than against A.1, B.1.420, B.1.111-I, and B.1.111-II, respectively. However, molecular epidemiological data indicate that there is no increase in the transmissibility rate associated with this new lineage. Hence, although the evidence provided in this study support a Variant of Interest Status (VOI) for the B1+L249S+E484K lineage, enhanced laboratory characterization of this particular lineage and other emerging lineages with the E484K mutation should be carried out in individuals with immunity acquired by natural infection and vaccination. This study accentuated the capability of new variants with the E484K mutation to be resistant to neutralization by humoral immunity, and therefore the need to intensify surveillance programs.HIGHLIGHT⍰ The E484K mutation in B.1+L249S+E484K appears not to affect the viral titer⍰ Sensitivity of lineages without E484K mutation to neutralizing antibodies did not change⍰ B.1+L249S+E484K lineage shows a reduction in its neutralizing capacityCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funds from the Fundacion Banco Nacional de Sangre Hemolife (CEMIN-10-2020) and the Instituto Nacional de Salud, Bogota D.C, Colombia (CORHUCO project).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was done between November 2020 and February 2021 and conducted in compliance with ethical principles of the Declaration of Helsinki and to the conditions provided by the Ministry of Health - Colombia. All subjects enrolled in this research responded voluntarily to an informed consent formulary previously approved by the Ethics committee of Colombian National Health Institute, Comite de Etica y de Metodologias de Investigacion (CEMIN)-10-2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary material.